These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 21445974

  • 1. Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway.
    Yeramian A, Sorolla A, Velasco A, Santacana M, Dolcet X, Valls J, Abal L, Moreno S, Egido R, Casanova JM, Puig S, Vilella R, Llombart-Cussac A, Matias-Guiu X, Martí RM.
    Int J Cancer; 2012 Feb 15; 130(4):967-78. PubMed ID: 21445974
    [Abstract] [Full Text] [Related]

  • 2. Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.
    Lyros O, Mueller A, Heidel F, Schimanski CC, Gockel I, Galle PR, Lang H, Moehler M.
    Int J Cancer; 2010 Sep 01; 127(5):1197-208. PubMed ID: 20039326
    [Abstract] [Full Text] [Related]

  • 3. Sunitinib induces apoptosis in pheochromocytoma tumor cells by inhibiting VEGFR2/Akt/mTOR/S6K1 pathways through modulation of Bcl-2 and BAD.
    Saito Y, Tanaka Y, Aita Y, Ishii KA, Ikeda T, Isobe K, Kawakami Y, Shimano H, Hara H, Takekoshi K.
    Am J Physiol Endocrinol Metab; 2012 Mar 15; 302(6):E615-25. PubMed ID: 21878661
    [Abstract] [Full Text] [Related]

  • 4. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
    Que W, Chen J, Chuang M, Jiang D.
    APMIS; 2012 Mar 15; 120(3):195-203. PubMed ID: 22339676
    [Abstract] [Full Text] [Related]

  • 5. Blockade of NFκB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells.
    Sorolla A, Yeramian A, Valls J, Dolcet X, Bergadà L, Llombart-Cussac A, Martí RM, Matias-Guiu X.
    Mol Oncol; 2012 Oct 15; 6(5):530-41. PubMed ID: 22819259
    [Abstract] [Full Text] [Related]

  • 6. Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas.
    Cassol CA, Winer D, Liu W, Guo M, Ezzat S, Asa SL.
    Mod Pathol; 2014 Aug 15; 27(8):1050-62. PubMed ID: 24390213
    [Abstract] [Full Text] [Related]

  • 7. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
    Bai L, Yang JC, Ok JH, Mack PC, Kung HJ, Evans CP.
    Int J Cancer; 2012 Jun 01; 130(11):2693-702. PubMed ID: 21792888
    [Abstract] [Full Text] [Related]

  • 8. Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway.
    Chen KF, Yeh PY, Hsu C, Hsu CH, Lu YS, Hsieh HP, Chen PJ, Cheng AL.
    J Biol Chem; 2009 Apr 24; 284(17):11121-33. PubMed ID: 19261616
    [Abstract] [Full Text] [Related]

  • 9. PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation.
    Sabbatino F, Wang Y, Wang X, Flaherty KT, Yu L, Pepin D, Scognamiglio G, Pepe S, Kirkwood JM, Cooper ZA, Frederick DT, Wargo JA, Ferrone S, Ferrone CR.
    Oncotarget; 2014 Apr 15; 5(7):1926-41. PubMed ID: 24732172
    [Abstract] [Full Text] [Related]

  • 10. MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer.
    Cortes-Sempere M, Chattopadhyay S, Rovira A, Rodriguez-Fanjul V, Belda-Iniesta C, Tapia M, Cejas P, Machado-Pinilla R, Manguan-García C, Sánchez-Pérez I, Nistal M, Moratilla C, de Castro-Carpeño J, Gonzalez-Barón M, Albanell J, Perona R.
    Cancer Lett; 2009 Dec 28; 286(2):206-16. PubMed ID: 19553005
    [Abstract] [Full Text] [Related]

  • 11. Receptor Tyrosine Kinase Expression Predicts Response to Sunitinib in Breast Cancer.
    Spanheimer PM, Lorenzen AW, De Andrade JP, Kulak MV, Carr JC, Woodfield GW, Sugg SL, Weigel RJ.
    Ann Surg Oncol; 2015 Dec 28; 22(13):4287-94. PubMed ID: 25971960
    [Abstract] [Full Text] [Related]

  • 12. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.
    Patyna S, Laird AD, Mendel DB, O'farrell AM, Liang C, Guan H, Vojkovsky T, Vasile S, Wang X, Chen J, Grazzini M, Yang CY, Haznedar JO, Sukbuntherng J, Zhong WZ, Cherrington JM, Hu-Lowe D.
    Mol Cancer Ther; 2006 Jul 28; 5(7):1774-82. PubMed ID: 16891463
    [Abstract] [Full Text] [Related]

  • 13. Potentiation of bortezomib-induced apoptosis by TGF-beta in cultured human Tenon's fibroblasts: contribution of the PI3K/Akt signaling pathway.
    Chung EJ, Moon SW, Jung SA, Cho YJ, Kim SW, Lee JH.
    Invest Ophthalmol Vis Sci; 2010 Dec 28; 51(12):6232-7. PubMed ID: 20702821
    [Abstract] [Full Text] [Related]

  • 14. Tyrosine kinase receptor inhibitor-targeted combined chemotherapy for metastatic bladder cancer.
    Wu CL, Ping SY, Yu CP, Yu DS.
    Kaohsiung J Med Sci; 2012 Apr 28; 28(4):194-203. PubMed ID: 22453067
    [Abstract] [Full Text] [Related]

  • 15. Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer.
    Fenton MS, Marion KM, Salem AK, Hogen R, Naeim F, Hershman JM.
    Thyroid; 2010 Sep 28; 20(9):965-74. PubMed ID: 20629553
    [Abstract] [Full Text] [Related]

  • 16. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
    Festuccia C, Muzi P, Millimaggi D, Biordi L, Gravina GL, Speca S, Angelucci A, Dolo V, Vicentini C, Bologna M.
    Endocr Relat Cancer; 2005 Dec 28; 12(4):983-98. PubMed ID: 16322337
    [Abstract] [Full Text] [Related]

  • 17. CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells.
    Lin YC, Chen KC, Chen CC, Cheng AL, Chen KF.
    Oral Oncol; 2012 Jul 28; 48(7):585-93. PubMed ID: 22342571
    [Abstract] [Full Text] [Related]

  • 18. Sunitinib inhibits catecholamine synthesis and secretion in pheochromocytoma tumor cells by blocking VEGF receptor 2 via PLC-γ-related pathways.
    Aita Y, Ishii KA, Saito Y, Ikeda T, Kawakami Y, Shimano H, Hara H, Takekoshi K.
    Am J Physiol Endocrinol Metab; 2012 Oct 15; 303(8):E1006-14. PubMed ID: 22912364
    [Abstract] [Full Text] [Related]

  • 19. Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells.
    Tsapakidis K, Vlachostergios PJ, Voutsadakis IA, Befani CD, Patrikidou A, Hatzidaki E, Daliani DD, Moutzouris G, Liakos P, Papandreou CN.
    Int J Urol; 2012 Jun 15; 19(6):565-74. PubMed ID: 22324515
    [Abstract] [Full Text] [Related]

  • 20. Effect of SU11248 on gastrointestinal stromal tumor-T1 cells: enhancement of growth inhibition via inhibition of 3-kinase/Akt/mammalian target of rapamycin signaling.
    Ikezoe T, Yang Y, Nishioka C, Bandobashi K, Nakatani H, Taguchi T, Koeffler HP, Taguchi H.
    Cancer Sci; 2006 Sep 15; 97(9):945-51. PubMed ID: 16916320
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.